GTS Securities’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.6M Buy
+75,048
New +$3.22M 0.08% 153
2026
Q1
Sell
-4,391
Closed -$223K 1727
2025
Q4
$223K Buy
+4,391
New +$225K 0.01% 1225
2025
Q3
Sell
-3,163
Closed -$218K 1621
2025
Q2
$218K Buy
3,163
+26
+0.8% +$1.77K 0.01% 1078
2025
Q1
$218K Buy
+3,137
New +$259K 0.01% 1121
2024
Q4
Sell
-8,929
Closed -$1.06M 3154
2024
Q3
$1.06M Sell
8,929
-1,908
-18% -$254K ﹤0.01% 2108
2024
Q2
$1.55M Sell
10,837
-17,162
-61% -$2.27M ﹤0.01% 1704
2024
Q1
$3.6M Buy
27,999
+12,992
+87% +$1.55M 0.01% 1080
2023
Q4
$1.55M Buy
15,007
+2,350
+19% +$232K ﹤0.01% 1842
2023
Q3
$1.15M Sell
12,657
-21,517
-63% -$1.9M ﹤0.01% 1902
2023
Q2
$2.77M Buy
+34,174
New +$2.79M 0.09% 212

Other funds holding NVO

GTS Securities's NVO Position: Q2 2026 in Review

GTS Securities opened a new position in Novo Nordisk (NVO) in Q2 2026: 75,048 shares worth $3.6M. The stake represents 0.08% of the portfolio and ranks #153 among its holdings. This is a return to the name: GTS Securities previously reported a position in NVO as recently as Q4 2025.

GTS Securities first reported a position in NVO in Q2 2023 and has held it in 10 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • GTS Securities held 75,048 shares of Novo Nordisk worth $3.6M as of Q2 2026.
  • Novo Nordisk was a new GTS Securities position in Q2 2026.
  • Novo Nordisk made up 0.08% of GTS Securities's portfolio in Q2 2026, its #153 holding.
  • GTS Securities first reported a position in Novo Nordisk in Q2 2023 and has held it in 10 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.